Journals / Kafkas Üniversitesi Veteriner Fakültesi Dergisi / 2013 / Cilt: 19 - Sayı: 0

Korneal neovaskularizasyonun subkonjonktival Ranibizumab ve bevacizumab enjeksiyonu ile tavşan korneasında inhibisyonu

Inhibition of corneal neovascularization by subconjunctival injection of Ranibizumab and bevacizumab in rabbit cornea

Pages
125–132
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Ranibizumab seemed more effective than bevacizumab on inhibiting corneal neovascularization in the rabbit cornea.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to evaluate the effects of subconjunctival ranibizumab and bevacizumab injection on angiogenesis in the rabbit cornea.
📊
Key Findings & Data:The corneas of 24 New Zealand rabbits were cauterized with silver nitrate to induce neovascularization.
💡
Conclusion & Impact:Ranibizumab seemed more effective than bevacizumab on inhibiting corneal neovascularization in the rabbit cornea.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this study was to evaluate the effects of subconjunctival ranibizumab and bevacizumab injection on angiogenesis in the rabbit cornea. The corneas of 24 New Zealand rabbits were cauterized with silver nitrate to induce neovascularization. The eyes were irrigated with 10 ml of 0.9% saline solution. The alkaline burns were similar in all the rabbits. At the 24 h after cauterization, the rabbits were divided into three groups of eight animals each: The first group (GC) received 0.02 ml 0.9% saline solution as a control group whereas second (GR) and third (GB) groups received 0.5 mg ranibizumab and 1.25 mg bevacizumab by subconjunctival injection, respectively, on days first and 7 after lesion. The rabbits’ corneas were extracted on the 14th day. Digital photographs of the corneas were obtained and the newly formed vessels were analyzed in a computerized system (google sketch-up program). The rates of these vessels were compared between the groups. Ranibizumab and bevacizumab were both effective on inhibition of angiogenesis, in comparison to 0.9% saline solution (P<0.05). Ranibizumab was found to be statistically more effective to reduce corneal neovascularization than bevacizumab (P<0.05). Bevacizumab and ranibizumab were found to be effective in inhibiting the corneal neovascularization in the rabbit cornea. Ranibizumab seemed more effective than bevacizumab on inhibiting corneal neovascularization in the rabbit cornea.

Özet

Bu çalışmanın amacı; subkonjunktival olarak uygulanan ranibizumab and bevacizumab’ın tavşan korneasında anjiyogenezis üzerine etkilerini değerlendirmekti. Yirmi dört adet Yeni Zelanda tavşanının korneaları neovaskülarizasyon oluşturmak için gümüş nitrat ile koterize edildi. Gözler 10 ml %0.9 salin solusyonu ile yıkandı. Tüm gözlerde eşit miktarda kimyasal yanık oluşturulmasına dikkat edildi. Koterizasyon sonrası 24. saatte tavşanlar üç gruba ayrıldı: Kontrol grubuna (GC) (n=8) subkonjunktival 0.02 ml %0.9‘luk salin solüsyonu; Grub Ranibizumab’a (GR) (n=8) subkonjunktival olarak 0.5 mg ranibizumab ve Grup Bevasizumab’a (GB) (n=8) ise subkonjunktival olarak 1.25 mg bevacizumab 1. ve 7. günlerde uygulandı Topical antibiotik tedavisi sonrası, tavşan korneaları 14. günde çıkarıldı. Korneaların digital fotoğrafları alınarak yeni oluşmuş damarlar bilgisayar programı (google sketch-up programı) yardımıyla analiz edildi. Yeni oluşan damar yapılarının alanının kornea alanına oranları gruplar arasında değerlendirildi. Ranibizumab ve Bevasizumab’ın her ikisi de anjiyogenez inhibisyonunda %0.9 salin solüsyonuna kıyasla (P<0.05) daha etkili olduğu saptandı.Ranibizumab’ın korneal neovaskülarizasyon azaltıcı etkisi Bevasizumab’tan istatistiksel olarak anlamlı (P<0.05) derecede fazla bulundu. Bevasizumab ve Ranibizumab’ın tavşan korneasında neovaskularizasyonu inhibe etmekte etkili olduğu tespit edildi. Ranibizumabın tavşan korneasında neovaskülarizasyonu inhibe edici etkisinin Bevasizumab’tan daha fazla olduğu saptandı.

🔖

Cite This Article

EKİNCİ, M., ÇAĞATAY, H. H., YAZAR, Z., BİNGÖL, S. A., KAPLAN, A. (2013). Korneal neovaskularizasyonun subkonjonktival Ranibizumab ve bevacizumab enjeksiyonu ile tavşan korneasında inhibisyonu. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 19 - Sayı: 0, 125–132. https://ajindex.com/articles/273680

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ambati Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J: Corneal avascularity is due to soluble VEGF receptor-1. Nature, 443, 993-997, 2006
  2. Chang JH, Gabison EE, Kato T, Azar DT: Corneal neovascularization. Curr Opin Ophthalmol, 12 (4): 242-249, 2001
  3. Azar DT: Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc, 104, 264-302, 2006
  4. Kato T, Kure T, Chang JH, Gabison EE, Itoh T, Itohara S, Azar DT: Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett, 508, 187-190, 2001
  5. Usui T, Yamagami S, Kishimoto S, Seiich Y, Nakayama T, Amano S: Role of macrophage migration inhibitory factor in corneal neovascularization. Invest Ophthalmol Vis Sci, 48 (8): 3545-3550, 2007
  6. Ambati BK, Anand A, Joussen AM, Kuziel WA, Adamis AP, Ambati J: Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci, 44 (2): 590-593, 2003
  7. Philipp W, Speicher L, Humpel C: Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci, 41 (9): 2514-2522, 2000
  8. Arevalo JF, Sanchez JG, Fromow-Guerra J, Wu L, Berrocal MH, Farah ME, Cardillo J, Rodríguez FJ; Pan-American Collaborative Retina Study Group (PACORES): Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12- month follow-up. Graefes Arch Clin Exp Ophthalmol, 247 (6): 735-743, 2009
  9. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A: Sub-conjunctival bevacizumab injection for corneal neovascularization. Cornea, 27 (2): 142-147, 2008
  10. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI: The effect of topical bevacizumab on corneal neovascularization. Ophthalmology, 115 (6): 33-38, 2008
  11. Uy HS, Chan PS, Ang RE: Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson Syndrome. Cornea, 27(1), 70-73, 2008 12. Doctor